uniQure N.V. (QURE) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 1.73
30Y Low1.7·High1.7
P/FCF
N/A
—
5yr avg: 3.59
30Y Low3.6·High39.0
P/B Ratio
↑
6.98
↑+127% vs avg
5yr avg: 3.08
30Y Low1.6·High8.9
ROE
↓
-207.1%
↑-115% vs avg
5yr avg: -96.2%
30Y Low-238%·High79%
Debt/EBITDA
N/A
—
5yr avg: 0.43
30Y Low0.4·High0.4
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
QURE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
uniQure N.V. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.5B | $1.4B | $859M | $323M | $1.1B | $971M | $1.6B | $2.9B | $1.0B | $529M | $140M |
| Enterprise Value | $1.9B | $1.8B | $766M | $220M | $974M | $551M | $1.4B | $2.6B | $828M | $389M | $28M |
| P/E Ratio → | -6.98 | — | — | — | — | 2.95 | — | — | — | — | — |
| P/S Ratio | 92.42 | 85.48 | 31.68 | 20.37 | 9.95 | 1.85 | 42.83 | 393.68 | 91.03 | 40.33 | 5.59 |
| P/B Ratio | 6.98 | 6.92 | — | 1.55 | 2.23 | 1.63 | 6.59 | 8.87 | 5.72 | 5.88 | 2.20 |
| P/FCF | — | — | — | — | — | 3.59 | — | — | — | — | — |
| P/OCF | — | — | — | — | — | 3.37 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
QURE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 113.83 | 28.26 | 13.87 | 9.15 | 1.05 | 38.20 | 351.82 | 73.35 | 29.71 | 1.11 |
| EV / EBITDA | — | — | — | — | — | 1.73 | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | 1.77 | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | 2.04 | — | — | — | — | — |
QURE Profitability
Margins and return-on-capital ratios measuring operating efficiency
uniQure N.V. earns an operating margin of -1166.8%. Operating margins have expanded from -1785.5% to -1166.8% over the past 3 years, signaling improving operational efficiency. A negative ROE of -207.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.5% | 89.5% | 32.4% | 14.0% | 96.9% | 95.2% | -226.3% | 100.0% | -547.5% | -414.3% | -189.6% |
| Operating Margin | -1166.8% | -1166.8% | -679.6% | -1785.5% | -134.4% | 59.3% | -334.3% | -1663.8% | -781.9% | -549.0% | -286.7% |
| Net Profit Margin | -1236.0% | -1236.0% | -883.4% | -1947.1% | -119.1% | 62.9% | -333.3% | -1705.8% | -738.2% | -613.3% | -292.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -207.1% | -207.1% | -238.5% | -90.2% | -23.7% | 78.5% | -44.1% | -49.4% | -61.8% | -104.7% | -75.5% |
| ROA | -28.8% | -28.8% | -34.5% | -40.1% | -16.7% | 57.3% | -31.7% | -34.4% | -34.5% | -40.3% | -32.3% |
| ROIC | -50.7% | -50.7% | -5422.5% | -85.6% | -37.9% | 189.6% | -211.8% | — | — | — | — |
| ROCE | -29.4% | -29.4% | -28.9% | -40.8% | -20.4% | 57.2% | -34.4% | -36.1% | -39.8% | -40.3% | -35.5% |
QURE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $456M ($537M total debt minus $80M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.70 | 2.70 | — | 0.67 | 0.30 | 0.23 | 0.29 | 0.23 | 0.20 | 0.22 | 0.32 |
| Debt / EBITDA | — | — | — | — | — | 0.43 | — | — | — | — | — |
| Net Debt / Equity | — | 2.29 | — | -0.50 | -0.18 | -0.71 | -0.71 | -0.94 | -1.11 | -1.55 | -1.76 |
| Net Debt / EBITDA | — | — | — | — | — | -1.32 | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | -1.55 | — | — | — | — | — |
| Interest Coverage | -2.12 | -2.12 | -2.72 | -6.38 | -9.96 | 41.70 | -35.98 | -31.60 | -37.46 | -31.20 | -32.25 |
QURE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
uniQure N.V.'s current ratio of 10.43x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 8.85x to 10.43x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.43 | 10.43 | 9.74 | 8.85 | 6.28 | 17.09 | 9.47 | 12.15 | 11.85 | 8.44 | 6.34 |
| Quick Ratio | 10.43 | 10.43 | 9.74 | 8.68 | 6.19 | 17.09 | 9.47 | 12.15 | 11.79 | 8.38 | 6.29 |
| Cash Ratio | 9.89 | 9.89 | 9.18 | 8.39 | 4.65 | 15.13 | 8.96 | 11.94 | 11.76 | 8.26 | 5.83 |
| Asset Turnover | — | 0.02 | 0.05 | 0.02 | 0.15 | 0.65 | 0.11 | 0.02 | 0.04 | 0.06 | 0.13 |
| Inventory Turnover | — | — | — | 1.13 | 0.48 | — | — | — | 65.47 | 59.18 | 72.98 |
| Days Sales Outstanding | — | 293.37 | 79.15 | 96.60 | 350.92 | 40.94 | 64.39 | 47.47 | 7.54 | 44.17 | 133.50 |
QURE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
uniQure N.V. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 33.9% | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | 27.8% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $58M | $49M | $48M | $47M | $47M | $44M | $40M | $36M | $27M | $25M |
Peer Comparison
Compare QURE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 QUREYou | $1B | -7.0 | — | — | 89.5% | -1166.8% | -207.1% | -50.7% | — |
 SRPT | $2B | -2.9 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 BMRN | $10B | 30.1 | 15.9 | 14.4 | 77.1% | 16.6% | 5.9% | 7.4% | 1.0 |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 SGMO | $22M | -0.2 | — | — | 100.0% | -179.9% | -185.4% | -178.8% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 ARWR | $11B | -6389.3 | 90.4 | 69.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
See QURE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs QURE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare QURE vs SRPT
Side-by-side business, growth, and profitability comparison vs Sarepta Therapeutics, Inc..
Start ComparisonQURE — Frequently Asked Questions
Quick answers to the most common questions about buying QURE stock.
What is uniQure N.V.'s P/E ratio?
uniQure N.V.'s current P/E ratio is -7.0x. The historical average is 2.9x.
What is uniQure N.V.'s ROE?
uniQure N.V.'s return on equity (ROE) is -207.1%. The historical average is -87.7%.
Is QURE stock overvalued?
Based on historical data, uniQure N.V. is trading at a P/E of -7.0x. Compare with industry peers and growth rates for a complete picture.
What are uniQure N.V.'s profit margins?
uniQure N.V. has 89.5% gross margin and -1166.8% operating margin.